Bookmark and Share

Heathics Paris France, pharmaceutical industry consultant, pharmaceutical laboratory consultant team,  study, trial, consultant, paediatric investigational plan, registration files ctd,

Heathics Paris France, pharmaceutical industry consultant, pharmaceutical laboratory consultant team,  study, trial, consultant, paediatric investigational plan, registration files ctd,
Heathics Paris France, pharmaceutical industry consultant, pharmaceutical laboratory consultant team,  study, trial, consultant, paediatric investigational plan, registration files ctd,
  pharmaceutical industry consulting in France, pharmaceutical laboratory consulting, drug safety, clinical study, medical market consultants, scientific communication consulting,
 





Heathics health pharmaceutical industry consultant

health pharmaceutical industry consultant

Heathics partners

Values health pharmaceutical industry consultant


Heathics Paris France, pharmaceutical industry consultant, pharmaceutical laboratory consultant team,  study, trial, consultant, paediatric investigational plan, registration files ctd,




Didier Terracol obtained his Pharm D and DEPS; he is specialized in Industrial Pharmaceutical Technology. He was one of the founding members of Dakota Pharm (1987) with the position of General Manager and QP. In 1992, he was founding member, General Manager and QP of the pharmaceutical company Effik. As President of Stratégie Santé since 2010 he brings to HEATHICS his expertise in the pharmaceutical development.




Al Lodola is graduated from the University of Bath UK and obtained his PhD from the University of Bristol, UK. After 7 years as a lecturer in Biochemistry at the University of Kent, Canterbury, UK he joined Pfizer at their Centre de Recherche in Amboise France. After some years spent working on in vitro toxicology, Al became head of the General and Reproductive Toxicology Department. From this position, he joined the Toxicology Headquarters Group located at the Pfizer Global Research and Development headquarters in New London , Connecticut, USA. He gained a wide expertise in regulatory interactions as a member of the Pfizer teams which developed and took to market a number of development candidates. Returning from the USA after 5-years he established himself as a nonclinical consultant.




Frédérique Emery-Morel is graduated in biotechnology and epidemiology from the University of Sciences, Grenoble in France and from the school of Medicine in Paris, France, respectively. She spent more than 20 years in the pharmaceutical industry working in Research & Development and Medical Affairs. She participated to the international development and post-marketing follow-up of cardio-vascular bone diseases and women health drugs with main responsibilities in clinical research and pharmacovigilance.

Frédérique has acquired a large experience in the conduct of international clinical studies from phase II to phase IV as well as in the safety follow-up of marketed drugs. As a pharmacovigilance manager she has been involved in new-drug registration dossiers, answers to regulatory authorities about drug safety from the EMA, FDA, ansm, risk management plans and international PSURs writing.








Heathics
111, rue des Tennerolles - 92210 Saint Cloud, France
Phone/Fax : 33+ (0)1 46 02 19 30.


Links


Conception - réalisation
lagencecdrs.com